Intestinal CYP3A4 is not involved in the enantioselective disposition of lansoprazole

Xenobiotica

Volumn 36, Issue 1, 2006, Pages 95-102

  Miura, M ^a   Kagaya, H ^a   Tada, H ^a   Uno, T ^b   Yasui Furukori, N ^b   Tateishi, T ^b   Suzuki, T ^a  

^a AKITA UNIVERSITY HOSPITAL   (Japan)

^b HIROSAKI UNIVERSITY   (Japan)

Author keywords

CYP3A4; Enantiomer; Grapefruit juice; Lansoprazole

Indexed keywords

CYTOCHROME P450 3A4; LANSOPRAZOLE; WATER;

ADULT; ARTICLE; CATALYSIS; CONCENTRATION (PARAMETERS); DRUG DISPOSITION; DRUG HALF LIFE; ENANTIOSELECTIVITY; GENOTYPE; GRAPEFRUIT JUICE; HOMOZYGOSITY; HUMAN; NORMAL HUMAN; STEREOCHEMISTRY; SULFOXIDATION;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADMINISTRATION, ORAL; ADULT; BEVERAGES; CITRUS PARADISI; CYTOCHROME P-450 ENZYME SYSTEM; FEMALE; HUMANS; INTESTINES; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; OMEPRAZOLE; STEREOISOMERISM;

CITRUS X PARADISI;

EID: 33644618160     PISSN: 00498254     EISSN: None     Source Type: Journal    
DOI: 10.1080/00498250500485065     Document Type: Article

References (20)

1. Ameer B and Weintraub RA. 1997. Drug interactions with grapefruit juice. Clinical Pharmacokinetics 33:103-121.
2. Andersson T. 1996. Pharmacokinetics, metabolism and interactions of acid pump inhibitors. Focus on omeprazole, lansoprazole and pantoprazole. Clinical Pharmacokinetics 31:9-28.
3. Bailey DG, Malcolm J, Arnold O, Spence JD. 1998. Grapefruit juice-drug interactions. British Journal of Clinical Pharmacology 46:101-110.
4. De Morais SM, Wilkinson GR, Blaisdell J, Meyer UA, Nakamura K, Goldstein JA. 1994. Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Molecular Pharmacology 46:594-598.
5. Hall SD, Thummel KE, Watkins PB, Lown KS, Benet LZ, Paine MF, Mayo RR, Turgeon DK, Bailey DG, Fontana RJ, Wrighton SA. 1999. Molecular and physical mechanisms of first-pass extraction. Drug Metabolism and Disposition 27:161-166.
6. Katsuki H, Hamada A, Nakamura C, Arimori K, Nakano M. 2001. Role of CYP3A4 and CYP2C19 in the stereoselective metabolism of lansoprazole by human liver microsomes. European Journal of Clinical Pharmacology 57:709-715.
7. Katsuki H, Nakamura C, Arimori K, Fujiyama S, Nakano M. 1997. Genetic polymorphism of CYP2C19 and lansoprazole pharmacokinetics in Japanese subjects. European Journal of Clinical Pharmacology 52:391-396.
8. Kim KA, Kim MJ, Park JY, Shon JH, Yoon YR, Lee SS, Liu KH, Chun JH, Hyun MH, Shin JG. 2003. Stereoselective metabolism of lansoprazole by human liver cytochrome P450 enzymes. Drug Metabolism and Disposition 31:1227-1234.
9. Kolars JC, Lown KS, Schmiedlin-Ren P, Ghosh M, Fang C, Wrighton SA, Merion RM, Watkins PB. 1994. CYP3A gene expression in human gut epithelium. Pharmacogenetics 4:247-259.
10. Miura M, Tada H, Suzuki T. 2004b. Simultaneous determination of lansoprazole enantiomers and their metabolites in plasma by liquid chromatography with solid-phase extraction. Journal of Chromatography B 804:389-395.
11. Miura M, Tada H, Yasui-Furukori N, Uno T, Sugawara K, Tateishi T, Suzuki T. 2004a. Pharmacokinetic differences between the enantiomers of lansoprazole and its metabolite, 5-hydroxylansoprazole, in relation to CYP2C19 genotypes. European Journal of Clinical Pharmacology 60:623-628.
12. Miura M, Tada H, Yasui-Furukori N, Uno T, Sugawara K, Tateishi T, Suzuki T. 2005a. The effect of clarithromycin on the enantioselective disposition of lansoprazole in relation to CYP2C19 genotypes. Chirality 17:338-344.
13. Miura M, Tada H, Yasui-Furukori N, Uno T, Sugawara K, Tateishi T, Suzuki T. 2005b. Enantioselective disposition of lansoprazole in relation to CYP2C19 genotypes in the presence of fluvoxamine. British Journal of Clinical Pharmacology 60:61-68.
14. Nagaya H, Satoh H, Maki Y. 1990. Possible mechanism for the inhibition of acid formation by the proton pump inhibitor AG-1749 in isolated canine parietal cells. Journal of Pharmacology and Experimental Therapeutics 252:1289-1295.
15. Pearce RE, Rodrigues AD, Goldstein JA, Parkinson A. 1996. Identification of the human P450 enzymes involved in lansoprazole metabolism. Journal of Pharmacology and Experimental Therapeutics 277:805-816.
16. Pichard L, Curi-Pedrosa R, Bonfils C, Jacqz-Aigrain E, Domerque J, Joyeux H, Cosme J, Guengerich FP. 1995. Oxidative metabolism of lansoprazole by human liver cytochromes P450. Molecular Pharmacology 47:410-418.
17. Prueksaritanont T, Gorham LM, Hochman JH, Tran LO, Vyas KP. 1996. Comparative studies of drug-metabolizing enzymes in dog, monkey, and human small intestines, and in Caco-2 cells. Drug Metabolism and Disposition 24:634-642.
18. Wacher VJ, Salphati L, Benet LZ. 2001. Active secretion and enterocytic drug metabolism barriers to drug absorption. Advanced Drug Delivery Reviews 46:89-102.
19. Watkins PB. 1997. The barrier function of CYP3A4 and P-glycoprotein in the small bowel. Advanced Drug Delivery Reviews 27:161-170.
20. Zhang QY, Dunbar D, Ostrowska A, Zeisloft S, Yang J, Kaminsky LS. 1999. Characterization of human small intestinal cytochromes P-450. Drug Metabolism and Disposition 27:804-809.